ADCT 502 - ADC Therapeutics

Drug Profile

ADCT 502 - ADC Therapeutics

Alternative Names: ADCT 502 ADC Therapeutics

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADC Therapeutics; Cancer Research Technology
  • Developer ADC Therapeutics
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 May 2018 ADC Therapeutics terminates a phase I trial in Solid tumours in USA due to safety reasons (NCT03125200)
  • 17 Apr 2017 Phase-I clinical trials in Solid tumours in USA (IV) (NCT03125200)
  • 05 Jan 2017 Preclinical trials in Solid tumours in United Kingdom (IV) (ADC Therapeutics pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top